PandemieGrippaleV1, Ncbi, Curation, bibRecord, 001662

H5N1 vaccines in humans

Identifieur interne : 001662 ( Ncbi/Curation ); précédent : 001661; suivant : 001663

H5N1 vaccines in humans

Auteurs : Mariana Baz [États-Unis] ; Catherine J. Luke [États-Unis] ; Xing Cheng ; Hong Jin ; Kanta Subbarao [États-Unis]

Source :

Virus research [ 0168-1702 ] ; 2013.

RBID : PMC:3795810

Descripteurs français

KwdFr :
- Animaux, Anticorps antiviraux (immunologie), Grippe humaine (), Grippe humaine (immunologie), Grippe humaine (virologie), Humains, Sous-type H5N1 du virus de la grippe A (génétique), Sous-type H5N1 du virus de la grippe A (immunologie), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (génétique), Vaccins antigrippaux (immunologie).
MESH :
- administration et posologie : Vaccins antigrippaux.
- génétique : Sous-type H5N1 du virus de la grippe A, Vaccins antigrippaux.
- immunologie : Anticorps antiviraux, Grippe humaine, Sous-type H5N1 du virus de la grippe A, Vaccins antigrippaux.
- virologie : Grippe humaine.
- Animaux, Grippe humaine, Humains.

English descriptors

KwdEn :
- Animals, Antibodies, Viral (immunology), Humans, Influenza A Virus, H5N1 Subtype (genetics), Influenza A Virus, H5N1 Subtype (immunology), Influenza Vaccines (administration & dosage), Influenza Vaccines (genetics), Influenza Vaccines (immunology), Influenza, Human (immunology), Influenza, Human (prevention & control), Influenza, Human (virology).
MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , genetics : Influenza Vaccines.
- chemical , immunology : Antibodies, Viral, Influenza Vaccines.
- genetics : Influenza A Virus, H5N1 Subtype.
- immunology : Influenza A Virus, H5N1 Subtype, Influenza, Human.
- prevention & control : Influenza, Human.
- virology : Influenza, Human.
- Animals, Humans.

Abstract

The spread of highly pathogenic avian H5N1 influenza viruses since 1997 and their virulence for poultry and humans has raised concerns about their potential to cause an influenza pandemic. Vaccines offer the most viable means to combat a pandemic threat. However, it will be a challenge to produce, distribute and implement a new vaccine if a pandemic spreads rapidly. Therefore, efforts are being undertaken to develop pandemic vaccines that use less antigen and induce cross-protective and long-lasting responses, that can be administered as soon as a pandemic is declared or possibly even before, in order to prime the population and allow for a rapid and protective antibody response. In the last few years, several vaccine manufacturers have developed candidate pandemic and pre-pandemic vaccines, based on reverse genetics and have improved the immunogenicity by formulating these vaccines with different adjuvants. Some of the important and consistent observations from clinical studies with H5N1 vaccines are as follows: two doses of inactivated vaccine are generally necessary to elicit the level of immunity required to meet licensure criteria, less antigen can be used if an oil-in-water adjuvant is included, in general antibody titers decline rapidly but can be boosted with additional doses of vaccine and if high titers of antibody are elicited, cross-reactivity against other clades is observed. Prime-boost strategies elicit a more robust immune response. In this review, we discuss data from clinical trials with a variety of H5N1 influenza vaccines. We also describe studies conducted in animal models to explore the possibility of reassortment between pandemic live attenuated vaccine candidates and seasonal influenza viruses, since this is an important consideration for the use of live vaccines in a pandemic setting.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795810

DOI: 10.1016/j.virusres.2013.05.006
PubMed: 23726847
PubMed Central: 3795810

Links toward previous steps (curation, corpus...)

to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000871
to stream Pmc, to step Curation: Pour aller vers cette notice dans l'étape Curation :000871
to stream Pmc, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000596
to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000A14
to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :000A14
to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000A09
to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001662

Links to Exploration step

PMC:3795810

Curation

No country items

Xing Cheng

<affiliation><nlm:aff id="A2">MedImmune, Mountain View, California.</nlm:aff>
<wicri:noCountry code="subfield">California.</wicri:noCountry>
</affiliation>

Hong Jin

<affiliation><nlm:aff id="A2">MedImmune, Mountain View, California.</nlm:aff>
<wicri:noCountry code="subfield">California.</wicri:noCountry>
</affiliation>

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">H5N1 vaccines in humans</title>
<author><name sortKey="Baz, Mariana" sort="Baz, Mariana" uniqKey="Baz M" first="Mariana" last="Baz">Mariana Baz</name>
<affiliation wicri:level="2"><nlm:aff id="A1">Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA.</nlm:aff>
<country xml:lang="fr" wicri:curation="lc">États-Unis</country>
<wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Luke, Catherine J" sort="Luke, Catherine J" uniqKey="Luke C" first="Catherine J" last="Luke">Catherine J. Luke</name>
<affiliation wicri:level="2"><nlm:aff id="A1">Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA.</nlm:aff>
<country xml:lang="fr" wicri:curation="lc">États-Unis</country>
<wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cheng, Xing" sort="Cheng, Xing" uniqKey="Cheng X" first="Xing" last="Cheng">Xing Cheng</name>
<affiliation><nlm:aff id="A2">MedImmune, Mountain View, California.</nlm:aff>
<wicri:noCountry code="subfield">California.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Jin, Hong" sort="Jin, Hong" uniqKey="Jin H" first="Hong" last="Jin">Hong Jin</name>
<affiliation><nlm:aff id="A2">MedImmune, Mountain View, California.</nlm:aff>
<wicri:noCountry code="subfield">California.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name>
<affiliation wicri:level="2"><nlm:aff id="A1">Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA.</nlm:aff>
<country xml:lang="fr" wicri:curation="lc">États-Unis</country>
<wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">23726847</idno>
<idno type="pmc">3795810</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795810</idno>
<idno type="RBID">PMC:3795810</idno>
<idno type="doi">10.1016/j.virusres.2013.05.006</idno>
<date when="2013">2013</date>
<idno type="wicri:Area/Pmc/Corpus">000871</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000871</idno>
<idno type="wicri:Area/Pmc/Curation">000871</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000871</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000596</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000596</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:23726847</idno>
<idno type="wicri:Area/PubMed/Corpus">000A14</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A14</idno>
<idno type="wicri:Area/PubMed/Curation">000A14</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A14</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000A09</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000A09</idno>
<idno type="wicri:Area/Ncbi/Merge">001662</idno>
<idno type="wicri:Area/Ncbi/Curation">001662</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">H5N1 vaccines in humans</title>
<author><name sortKey="Baz, Mariana" sort="Baz, Mariana" uniqKey="Baz M" first="Mariana" last="Baz">Mariana Baz</name>
<affiliation wicri:level="2"><nlm:aff id="A1">Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA.</nlm:aff>
<country xml:lang="fr" wicri:curation="lc">États-Unis</country>
<wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Luke, Catherine J" sort="Luke, Catherine J" uniqKey="Luke C" first="Catherine J" last="Luke">Catherine J. Luke</name>
<affiliation wicri:level="2"><nlm:aff id="A1">Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA.</nlm:aff>
<country xml:lang="fr" wicri:curation="lc">États-Unis</country>
<wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cheng, Xing" sort="Cheng, Xing" uniqKey="Cheng X" first="Xing" last="Cheng">Xing Cheng</name>
<affiliation><nlm:aff id="A2">MedImmune, Mountain View, California.</nlm:aff>
<wicri:noCountry code="subfield">California.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Jin, Hong" sort="Jin, Hong" uniqKey="Jin H" first="Hong" last="Jin">Hong Jin</name>
<affiliation><nlm:aff id="A2">MedImmune, Mountain View, California.</nlm:aff>
<wicri:noCountry code="subfield">California.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name>
<affiliation wicri:level="2"><nlm:aff id="A1">Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA.</nlm:aff>
<country xml:lang="fr" wicri:curation="lc">États-Unis</country>
<wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Virus research</title>
<idno type="ISSN">0168-1702</idno>
<idno type="eISSN">1872-7492</idno>
<imprint><date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antibodies, Viral (immunology)</term>
<term>Humans</term>
<term>Influenza A Virus, H5N1 Subtype (genetics)</term>
<term>Influenza A Virus, H5N1 Subtype (immunology)</term>
<term>Influenza Vaccines (administration & dosage)</term>
<term>Influenza Vaccines (genetics)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Influenza, Human (immunology)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Influenza, Human (virology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Anticorps antiviraux (immunologie)</term>
<term>Grippe humaine ()</term>
<term>Grippe humaine (immunologie)</term>
<term>Grippe humaine (virologie)</term>
<term>Humains</term>
<term>Sous-type H5N1 du virus de la grippe A (génétique)</term>
<term>Sous-type H5N1 du virus de la grippe A (immunologie)</term>
<term>Vaccins antigrippaux (administration et posologie)</term>
<term>Vaccins antigrippaux (génétique)</term>
<term>Vaccins antigrippaux (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term>
<term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A Virus, H5N1 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Sous-type H5N1 du virus de la grippe A</term>
<term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Grippe humaine</term>
<term>Sous-type H5N1 du virus de la grippe A</term>
<term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H5N1 Subtype</term>
<term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Grippe humaine</term>
<term>Humains</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p id="P1">The spread of highly pathogenic avian H5N1 influenza viruses since 1997 and their virulence for poultry and humans has raised concerns about their potential to cause an influenza pandemic. Vaccines offer the most viable means to combat a pandemic threat. However, it will be a challenge to produce, distribute and implement a new vaccine if a pandemic spreads rapidly. Therefore, efforts are being undertaken to develop pandemic vaccines that use less antigen and induce cross-protective and long-lasting responses, that can be administered as soon as a pandemic is declared or possibly even before, in order to prime the population and allow for a rapid and protective antibody response. In the last few years, several vaccine manufacturers have developed candidate pandemic and pre-pandemic vaccines, based on reverse genetics and have improved the immunogenicity by formulating these vaccines with different adjuvants. Some of the important and consistent observations from clinical studies with H5N1 vaccines are as follows: two doses of inactivated vaccine are generally necessary to elicit the level of immunity required to meet licensure criteria, less antigen can be used if an oil-in-water adjuvant is included, in general antibody titers decline rapidly but can be boosted with additional doses of vaccine and if high titers of antibody are elicited, cross-reactivity against other clades is observed. Prime-boost strategies elicit a more robust immune response. In this review, we discuss data from clinical trials with a variety of H5N1 influenza vaccines. We also describe studies conducted in animal models to explore the possibility of reassortment between pandemic live attenuated vaccine candidates and seasonal influenza viruses, since this is an important consideration for the use of live vaccines in a pandemic setting.</p>
</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Ncbi/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001662 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 001662 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    Ncbi
   |étape=   Curation
   |type=    RBID
   |clé=     PMC:3795810
   |texte=   H5N1 vaccines in humans
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i   -Sk "pubmed:23726847" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a PandemieGrippaleV1

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021

	Serveur d'exploration sur les pandémies grippales
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les pandémies grippales

H5N1 vaccines in humans

H5N1 vaccines in humans

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Curation

No country items

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki